Display options
Cite
Pettijohn E, Martone B, Rademaker A, et al. A phase I study of high-dose calcitriol in combination with temozolomide for patients with metastatic melanoma. J Pers Med. 2014;4(4):448-58doi: 10.3390/jpm4040448.
Pettijohn, E., Martone, B., Rademaker, A., & Kuzel, T. (2014). A phase I study of high-dose calcitriol in combination with temozolomide for patients with metastatic melanoma. Journal of personalized medicine, 4(4), 448-58. https://doi.org/10.3390/jpm4040448
Pettijohn, Erin, et al. "A phase I study of high-dose calcitriol in combination with temozolomide for patients with metastatic melanoma." Journal of personalized medicine vol. 4,4 (2014): 448-58. doi: https://doi.org/10.3390/jpm4040448
Pettijohn E, Martone B, Rademaker A, Kuzel T. A phase I study of high-dose calcitriol in combination with temozolomide for patients with metastatic melanoma. J Pers Med. 2014 Oct 17;4(4):448-58. doi: 10.3390/jpm4040448. PMID: 25563456; PMCID: PMC4282882.
Copy Download .nbib Format: NLM
Share it on

J Pers Med. 2014 Oct 17;4(4):448-58. doi: 10.3390/jpm4040448.

A phase I study of high-dose calcitriol in combination with temozolomide for patients with metastatic melanoma.

Journal of personalized medicine

Erin Pettijohn, Brenda Martone, Alfred Rademaker, Timothy Kuzel

Affiliations

  1. Division of Hematology/Oncology, Northwestern University, 676 N. St Clair, Suite 850, Chicago, IL 60611, USA. [email protected].
  2. Division of Hematology/Oncology, Northwestern University, 676 N. St Clair, Suite 850, Chicago, IL 60611, USA. [email protected].
  3. Division of Biostatistics, Department of Preventative Health, Feinberg School of Medicine, Northwestern University, 680 N. Lakeshore Drive, Suite 1400, Chicago, IL 60611, USA. [email protected].
  4. Division of Hematology/Oncology, Northwestern University, 676 N. St Clair, Suite 850, Chicago, IL 60611, USA. [email protected].

PMID: 25563456 PMCID: PMC4282882 DOI: 10.3390/jpm4040448

Abstract

BACKGROUND: Temozolomide is efficacious as an oral alternative for patients with metastatic melanoma (MM). Calcitriol has anti-proliferative properties and vitamin D receptor (VDR) polymorphisms are associated with alterations in melanoma susceptibility and progression.

METHODS: Tem 150 mg/m2 was administered on days 2-8 and 16-22 every 28 days. Calcitriol was given on days 1 and 15 every 28 days. VDR gene analysis was completed using PCR-RFLP based assays. Tolerability was the primary objective with secondary objectives of time to progression (TTP) and overall survival (OS).

RESULTS: Twenty pts with MM were registered. Cytopenias and thrombosis were the most common grade 3 or 4 toxicities. Median TTP was 1.8 mo. Pts with high-risk VDR genotype tt+/-ff (n = 6) had an OS of 3.8 mo from time of enrollment, compared to 7.4 mo for those with non-tt/ff genotypes (n = 11), although not statistically significant (HR = 1.20, 95% CI 0.41-3.53, p = 0.74).

CONCLUSIONS: The extended dosing of Tem with calcitriol is a well-tolerated regimen. The trend toward improved OS in non-tt/ff VDR genotypes is consistent with prior studies associating the tt/ff genotype with biologic aggressiveness.

References

  1. Exp Dermatol. 2009 Feb;18(2):97-108 - PubMed
  2. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
  3. J Clin Oncol. 2008 Sep 1;26(25):4189-99 - PubMed
  4. Br J Cancer. 2004 Aug 16;91(4):765-70 - PubMed
  5. J Clin Oncol. 2007 Apr 20;25(12 ):1470-5 - PubMed
  6. Br J Dermatol. 2007 Feb;156(2):277-82 - PubMed
  7. Eur J Cancer. 2011 Jul;47(10 ):1476-83 - PubMed
  8. Carcinogenesis. 2007 Feb;28(2):390-7 - PubMed
  9. J Clin Oncol. 2011 Jun 1;29(16):2191-8 - PubMed
  10. Endocrinology. 1981 Mar;108(3):1083-6 - PubMed
  11. J Invest Dermatol. 1988 Jun;90(6):834-40 - PubMed
  12. N Engl J Med. 2010 Aug 19;363(8):711-23 - PubMed
  13. J Clin Oncol. 2009 Aug 10;27(23 ):3861-7 - PubMed
  14. Oncology (Williston Park). 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8 - PubMed
  15. Melanoma Res. 2000 Feb;10(1):81-92 - PubMed
  16. J Lab Clin Med. 1999 Feb;133(2):120-8 - PubMed
  17. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  18. Clin Cancer Res. 2000 Feb;6(2):498-504 - PubMed
  19. J Clin Oncol. 2000 Jan;18(1):158-66 - PubMed
  20. Cancer. 2001 Jun 15;91(12):2431-9 - PubMed
  21. Mol Cell Endocrinol. 2001 May 25;177(1-2):161-71 - PubMed
  22. J Clin Oncol. 2007 Feb 20;25(6):669-74 - PubMed

Publication Types

Grant support